Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Bristol Myers Squibb Company. A complete text table follows the diagram.
Newer oncology, hematology and cardiovascular therapies now supply more than half of revenue, while Eliquis growth cushions steep declines across older brands
Swipe to explore
Legacy excluding Eliquis is $1,125M: reported Legacy Portfolio revenue less Eliquis and the reported $15M negative other-revenue item. A $1M reporting-rounding node reconciles displayed statement lines.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Growth Portfolio | 1 | $6.2B | 54.2% of revenue · +12% |
| Eliquis | 1 | $4.1B | Largest medicine · +16% |
| Other legacy medicines | 1 | $1.1B | Net of reported other-revenue item |
| Total revenue | 2 | $11.5B | 3% year-over-year growth |
| Statement rounding | 2 | $1M | Displayed-line reconciliation |
| Earnings before tax | 3 | $3.2B | 28.2% pretax margin |
| Cost of products sold | 3 | $3.4B | Manufacturing, royalties and alliances |
| SG&A | 3 | $1.6B | Commercial and corporate operations |
| R&D | 3 | $2.6B | 23.1% of revenue |
| Acquired IPR&D | 3 | $94M | External pipeline investment |
| Acquired-intangible amortization | 3 | $437M | Acquisition accounting |
| Other expense | 3 | $32M | Other items, net |
| Net earnings | 4 | $2.7B | After tax and rounding |
| Income tax | 4 | $561M | 17.3% effective rate |
| Statement rounding | 4 | $1M | Displayed-line reconciliation |
| Earnings attributable to BMS | 5 | $2.7B | $1.31 diluted EPS |
| Noncontrolling interest | 5 | $1M | Minority ownership |
| From | To | Value |
|---|---|---|
| Growth Portfolio | Total revenue | $6.2B |
| Eliquis | Total revenue | $4.1B |
| Other legacy medicines | Total revenue | $1.1B |
| Total revenue | Earnings before tax | $3.2B |
| Statement rounding | Earnings before tax | $1M |
| Total revenue | Cost of products sold | $3.4B |
| Total revenue | SG&A | $1.6B |
| Total revenue | R&D | $2.6B |
| Total revenue | Acquired IPR&D | $94M |
| Total revenue | Acquired-intangible amortization | $437M |
| Total revenue | Other expense | $32M |
| Earnings before tax | Net earnings | $2.7B |
| Earnings before tax | Income tax | $561M |
| Earnings before tax | Statement rounding | $1M |
| Net earnings | Earnings attributable to BMS | $2.7B |
| Net earnings | Noncontrolling interest | $1M |